Laparoscopic antireflux surgery in the lung transplant population

Lau, Christine L.; Palmer, Scott M.; Howell, David N.; McMahon, Ross L.; Hadjiliadis, Denis; Gaca, Jeffrey G.; Pappas, Theodore N.; Davis, Robert D.; Eubanks, Steve

doi:10.1007/s00464-001-8251-2

Cited by 70 publications

(46 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was confirmed that CF patients have an increased prevalence of acid reflux [21]. In addition, it has been shown that CF patients not only have acid but also nonacid reflux and, more often, proximal reflux when compared with other LTx recipients.…”

Section: Discussionmentioning

confidence: 82%

Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection

Blondeau¹,

Mertens²,

et al. 2007

View full text Add to dashboard Cite

Acid gastro-oesophageal reflux (GOR) and gastric aspiration have been labelled as risk factors for chronic rejection bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTx). The present study aimed to further characterise GOR (both acid and nonacid) and the degree of gastric aspiration in LTx recipients both with and without BOS.Impedance-pH recordings were used for GOR detection. Pepsin and bile acid levels were measured in bronchoalveolar lavage fluid (BALF).A total of 48% of patients had increased GOR, of which 27% had exclusively increased nonacid reflux. Cystic fibrosis patients had the highest prevalence of GOR. Pepsin was found in BALF of all patients and bile acids in BALF of 50% of the patients. Patients with BOS had neither increased GOR nor elevated pepsin in BALF. However, 70% of the patients with BOS had bile in BALF compared with 31% of stable patients. Proton pump inhibitor (PPI) treatment reduced acid reflux but did not affect nonacid reflux. Moreover, pepsin and bile levels in BALF were not reduced by PPI.One-half of the lung transplant patients had increased reflux, and nonacid reflux was common. Gastric aspiration occurred in most lung transplant patients. Pepsin was a more general marker and bile acids a more specific marker that might be associated with bronchiolitis obliterans syndrome. Proton pump inhibitor treatment did not prevent nonacid reflux and gastric aspiration.

show abstract

Section: Discussionmentioning

confidence: 82%

Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection

Blondeau¹,

Mertens²,

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Nissen fundoplication and Toupet fundoplication) can be performed safely on lung transplant candidates with advanced lung disease or lung transplant recipients with documented abnormal GOR [123,124,[127][128][129][132][133][134][135][136][137][138], thereby preventing reflux, aspiration of gastric secretions and related sequelae.…”

Section: Remarksmentioning

confidence: 99%

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

et al. 2014

View full text Add to dashboard Cite

Bronchiolitis obliterans syndrome (BOS) is a major complication of lung transplantation that is associated with poor survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society convened a committee of international experts to describe and/or provide recommendations for 1) the definition of BOS, 2) the risk factors for developing BOS, 3) the diagnosis of BOS, and 4) the management and prevention of BOS.A pragmatic evidence synthesis was performed to identify all unique citations related to BOS published from 1980 through to March, 2013. The expert committee discussed the available research evidence upon which the updated definition of BOS, identified risk factors and recommendations are based. The committee followed the GRADE (Grading of Recommendation, Assessment, Development and Evaluation) approach to develop specific clinical recommendations.The term BOS should be used to describe a delayed allograft dysfunction with persistent decline in forced expiratory volume in 1 s that is not caused by other known and potentially reversible causes of posttransplant loss of lung function. The committee formulated specific recommendations about the use of systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and about re-transplantation in patients with suspected and confirmed BOS.The diagnosis of BOS requires the careful exclusion of other post-transplant complications that can cause delayed lung allograft dysfunction, and several risk factors have been identified that have a significant association with the onset of BOS. Currently available therapies have not been proven to result in significant benefit in the prevention or treatment of BOS. Adequately designed and executed randomised controlled trials that properly measure and report all patient-important outcomes are needed to identify optimal therapies for established BOS and effective strategies for its prevention. Executive summaryMany lung transplant recipients develop delayed allograft dysfunction that has been traditionally referred to as bronchiolitis obliterans syndrome (BOS), which is thought to be caused by inflammation, destruction and fibrosis of small airways in the lung allograft that leads to obliterative bronchiolitis (OB). Because a definitive diagnosis of OB is difficult to make without a surgical lung biopsy, a decrease in the forced expiratory volume in 1 s (FEV1) has been used as a surrogate marker to identify patients who develop a syndrome of significant and persistent loss of lung allograft function with onset three or more months following transplantation. However, it is now recognised that numerous factors apart from OB can lead to a delayed onset, significant decline in lung function, and these causes of delayed onset graft dysfunction must be carefully excluded when a diagnosis of BOS is made. In general, BOS responds poorly to therapeutic interventions but may stabilise, and some patients may have a significant improvement in FEV1 with certain ther...

show abstract

“…Антирефлюксное хирургическое лечение (напри мер, фундопликация по Ниссену или Тупе) может быть безопасно выполнено у кандидатов на тран сплантацию с поздними стадиями хронических ле гочных заболеваний или у перенесших трансплан тацию легких с подтвержденным ГЭР [123,124,[127][128][129][132][133][134][135][136][137][138]; тем самым предотвращаются дальнейший рефлюкс и аспирация желудочного со держимого и связанные с ними осложнения.…”

Section: рекомендацияunclassified

International practical guidelines on diagnosis, prevention and treatment of bronchiolitis obliterans syndrome

Редакционная¹

2015

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

РезюмеСиндром облитерирующего бронхиолита (СОБ) -серьезное осложнение трансплантации легких, при котором сокращается выживае мость больных. Международным обществом по трансплантации легких и сердца, Американским торакальным и Европейским респира торным обществами созданы Международный комитет экспертов для разработки клинических рекомендаций по ведению пациентов с СОБ. В этих Рекомендациях дано определение СОБ, описаны факторы риска, диагностика, ведение больных и профилактика СОБ. Для разработки Рекомендаций собрана доказательная информация по СОБ с 1980 г. до марта 2013 г. Комитетом экспертов обсуждались доступные научные доказательства. Оценка Рекомендаций проводилась по системе GRADE. Термин СОБ относится к поздней дис функции трансплантата с неуклонным снижением объема форсированного выдоха за 1 ю секунду, необъяснимое другими причинами. В данных Рекомендациях обсуждаются вопросы использования системных глюкокортикостероидов, циклоспорина, такролимуса, азит ромицина и ретрансплантации у больных с предполагаемым и подтвержденным СОБ. В случае диагноза СОБ требуется тщательное исключение других посттрансплантационных осложнений с поздней дисфункцией трансплантата. Выявлено несколько факторов рис ка, тесно связанных с развитием СОБ. В настоящее время отсутствует лечение, при помощи которого можно бы предотвратить или существенно повлиять на СОБ. Для поиска оптимальных методов лечения и эффективных мер профилактики необходимы хорошо спланированные рандомизированные контролируемые исследования, в которых прослеживались бы все значимые для пациента пока затели. Ключевые слова: синдром облитерирующего бронхиолита, трансплантация легких, поздняя дисфункция трансплантата, клинические рекомендации, факторы риска, лечение. DOI: 10.18093/0869 0189 2015 25 4 403 424 International practical guidelines on diagnosis, prevention and treatment of bronchiolitis obliterans syndrome SummaryBronchiolitis obliterans syndrome (BOS) is a serious complication of lung transplantation that decreases the patients' survival. The International Society for Heart and Lung Transplantation, American Thoracic Society, and European Respiratory Society developed the current recommenda tions for better definition of BOS, describing risk factors for developing BOS, diagnosis, management and prevention of BOS. The recommenda tions were based on the evidenced data published from 1980 through to March, 2013 and were evaluated according to the GRADE system. The committee discussed the use of systemic corticosteroids, cyclosporine, tacrolimus, azithromycin and re transplantation in patients with BOS. The diagnosis of BOS should be made after exclusion of other post transplant complications that can cause persistent lung function decline. Currently, there is no therapy able to improve significantly or to prevent BOS development. Further randomised controlled trials are needed to search optimal therapies and preventive measures for BOS.

show abstract

Laparoscopic antireflux surgery in the lung transplant population

Cited by 70 publications

References 16 publications

Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection

Gastro-oesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection

An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome

International practical guidelines on diagnosis, prevention and treatment of bronchiolitis obliterans syndrome

Contact Info

Product

Resources

About